- Home
- LRE vs PSNL Comparison
LRE vs PSNL Comparison
Compare LRE & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRE | PSNL |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 872.1M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LRE | PSNL |
|---|---|---|
| Price | $1.43 | $8.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.71 |
| AVG Volume (30 Days) | 9.4K | ★ 1.8M |
| Earning Date | 07-30-2015 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.27 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $130,601,512.00 | $69,103,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.33 |
| P/E Ratio | $3.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $2.83 |
| 52 Week High | $2.97 | $11.40 |
Technical Indicators
Market Signals| Indicator | LRE | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 46.75 |
| Support Level | $1.25 | $7.68 |
| Resistance Level | $1.45 | $9.85 |
| Average True Range (ATR) | 0.06 | 0.59 |
| MACD | 0.02 | -0.23 |
| Stochastic Oscillator | 76.86 | 30.67 |
Price Performance
Historical ComparisonAbout LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.